Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely Purchases 175,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) CEO Lynn Seely acquired 175,000 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was purchased at an average cost of $0.61 per share, for a total transaction of $106,750.00. Following the transaction, the chief executive officer now owns 712,500 shares in the company, valued at approximately $434,625. The trade was a 32.56 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Lyell Immunopharma Stock Up 20.3 %

LYEL stock opened at $0.58 on Thursday. The firm has a 50 day moving average of $0.62 and a 200 day moving average of $0.89. The stock has a market capitalization of $171.76 million, a PE ratio of -0.74 and a beta of -0.41. Lyell Immunopharma, Inc. has a 52 week low of $0.48 and a 52 week high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, equities research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Institutional Trading of Lyell Immunopharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its stake in Lyell Immunopharma by 7.4% during the 4th quarter. Barclays PLC now owns 258,380 shares of the company’s stock valued at $165,000 after acquiring an additional 17,765 shares during the period. Wells Fargo & Company MN lifted its stake in Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock valued at $60,000 after acquiring an additional 20,542 shares during the period. Centiva Capital LP acquired a new stake in Lyell Immunopharma during the 3rd quarter valued at approximately $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Lyell Immunopharma by 13.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock valued at $197,000 after acquiring an additional 36,555 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Lyell Immunopharma during the 3rd quarter valued at approximately $52,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.